| PRECLINICAL | evidence | Comparison chart: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes. | Ozempic | — | 2025-11-24 |
| PRECLINICAL | evidence | Noninsulin drugs for type 2 diabetes. | Ozempic | — | 2025-11-24 |
| PRECLINICAL | evidence | Weight loss drugs: What do we know about the effects of Ozempic on children? | Ozempic | — | 2025-11-18 |
| PRECLINICAL | evidence | Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients. | Ozempic | — | 2025-11-15 |
| PRECLINICAL | evidence | Trump strikes deal with Ozempic and Mounjaro makers to cut prices of obesity injections. | Ozempic | — | 2025-11-07 |
| PRECLINICAL | evidence | Plastic Surgery in the Ozempidemic: Considerations for the Timing of Body Contouring Surgery in Patients with Semaglutide-Associated Weight Loss. | Ozempic | Weight & fat loss | 2025-11-01 |
| PRECLINICAL | evidence | Saying no to weight-loss drugs: The paradox of the ideal patient-consumer and stratified biomedicalization. | Ozempic | Weight & fat loss | 2025-11-01 |
| PRECLINICAL | evidence | Weight management treatment in obesity. | semaglutida | Weight & fat loss | 2025-11-01 |
| PRECLINICAL | evidence | Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes. | Ozempic | — | 2025-11-01 |
| PRECLINICAL | evidence | [Rapid weight loss through GLP-1 receptor agonists as lifestyle phenomenon and implications for plastic esthetic medicine]. | Ozempic | Weight & fat loss | 2025-11-01 |
| PRECLINICAL | evidence | Off-label ozempic and pancreatitis: legitimate concern or overblown fear? | Ozempic | — | 2025-11-01 |
| PRECLINICAL | evidence | Interest in Facial Volume Restorative Procedures With the Rise in "Ozempic Face": A Google Trends Analysis. | Ozempic | — | 2025-11-01 |
| PRECLINICAL | evidence | Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity. | Wegovy | Weight & fat loss | 2025-11-01 |
| PRECLINICAL | evidence | Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months). | Wegovy | Weight & fat loss | 2025-11-01 |
| PRECLINICAL | evidence | Permeation enhancer-induced membrane defects assist the oral absorption of peptide drugs. | Ozempic | — | 2025-10-28 |
| PRECLINICAL | evidence | Hypoglycaemic coma induced by a falsified semaglutide product: a case report. | Ozempic | — | 2025-10-21 |
| PRECLINICAL | evidence | Weight loss drugs: Doctor who prescribed Ozempic to her partner is suspended. | Ozempic | — | 2025-10-16 |
| PRECLINICAL | evidence | Semaglutide (Wegovy) for MASH. | Wegovy | — | 2025-10-13 |
| PRECLINICAL | evidence | Wegovy Now Approved for Treatment of Severe Liver Disease. | Wegovy | — | 2025-10-07 |
| PRECLINICAL | evidence | | Wegovy | — | 2025-10-01 |
| PRECLINICAL | evidence | [Semaglutide 2.4 mg (Wegovy(R)) for the management of clinical obesity with weight-related complications]. | Ozempic | Weight & fat loss | 2025-10-01 |
| PRECLINICAL | evidence | Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. | Ozempic | — | 2025-10-01 |
| PRECLINICAL | evidence | Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset. | Ozempic | Glycemic control | 2025-10-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly. | semaglutida | Weight & fat loss | 2025-10-01 |
| PRECLINICAL | evidence | Novel oral agents in anti-obesity pharmacotherapy: A narrative review. | Wegovy | Weight & fat loss | 2025-10-01 |
| PRECLINICAL | evidence | From prescription to trend: the misuse of Ozempic in the age of social media. | Ozempic | — | 2025-10-01 |
| PRECLINICAL | evidence | From MRI to Ozempic: breakthroughs that show why fundamental research must be protected. | Ozempic | — | 2025-10-01 |
| PRECLINICAL | evidence | Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application. | Wegovy | Weight & fat loss | 2025-10-01 |
| PRECLINICAL | evidence | Semaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health? | Wegovy | Glycemic control | 2025-10-01 |
| PRECLINICAL | evidence | How Glucagon-Like Peptide-1 Medications Are Depicted in Instagram Posts Regarding Women's Health, Nontraditional Access, and Barriers to Access: Content Analysis. | Ozempic | Glycemic control | 2025-09-04 |
| PRECLINICAL | evidence | Semaglutide in the Real World: Attitudes of the Population. | Ozempic | — | 2025-09-04 |
| PRECLINICAL | evidence | Slimming the risks: GLP-1 receptor agonist therapy may reduce in-hospital complications and hospital readmissions rates for hip fractures compared to obese patients not on these medications. | Ozempic | Weight & fat loss | 2025-09-02 |
| PRECLINICAL | evidence | Use and Potential Misuse of Glucagon-Like Peptide-1 Receptor Agonists in France: A Nationwide Cohort Study. | Ozempic | Glycemic control | 2025-09-01 |
| PRECLINICAL | evidence | GLP-1RA and the possible skin aging. | Ozempic | Glycemic control | 2025-09-01 |
| PRECLINICAL | evidence | Semaglutide and GLP-1 Agonists: Forensic and Medicolegal Implications. | Ozempic | Glycemic control | 2025-09-01 |
| PRECLINICAL | evidence | Wegovy approved for MASH. | Wegovy | — | 2025-09-01 |
| PRECLINICAL | evidence | Increased Weight Loss With the Combination of Levoketoconazole and Semaglutide in a Patient With Mild Hypercortisolism. | Ozempic | — | 2025-09-01 |
| PRECLINICAL | evidence | Navigating compounded semaglutide: what health care providers need to know. | Ozempic | Glycemic control | 2025-09-01 |
| PRECLINICAL | evidence | Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study. | Ozempic | Weight & fat loss | 2025-09-01 |
| PRECLINICAL | evidence | Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient. | Ozempic | — | 2025-09-01 |
| PRECLINICAL | evidence | Is Semaglutide Linked to NAION? A Case Report on a Rare Ocular Complication. | Ozempic | — | 2025-08-20 |
| PRECLINICAL | evidence | Drugs and devices for weight management. | Ozempic | — | 2025-08-04 |
| PRECLINICAL | evidence | Comparison table: Some drugs for weight management. | Wegovy | — | 2025-08-04 |
| PRECLINICAL | evidence | Response to "Weight-loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk". | Wegovy | — | 2025-08-01 |
| PRECLINICAL | evidence | A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss. | Wegovy | — | 2025-08-01 |
| PRECLINICAL | evidence | Weight loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk. | Wegovy | — | 2025-08-01 |
| PRECLINICAL | evidence | Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists. | Ozempic | Weight & fat loss | 2025-08-01 |
| PRECLINICAL | evidence | Youth Perspectives on the Use of Medications for Weight Loss. | Ozempic | Weight & fat loss | 2025-08-01 |
| PRECLINICAL | evidence | Advancements and challenges in the management of obesity using pharmacotherapy (Review). | Ozempic | — | 2025-08-01 |
| PRECLINICAL | evidence | Prescription weight loss medication use and eating disorder psychopathology among adolescent boys and young men from Canada and the United States. | Ozempic | Weight & fat loss | 2025-08-01 |